Table 1. Demographics and baseline description of the HAT patients and controls.
| Healthy controls | HAT stage 1 | HAT stage 2 | ||||||||
| DB289 | pentamidine | melarsoprol | eflornithine | |||||||
| n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | |
| Demographics | ||||||||||
| Number of patients (Total N = 526) | 61 | 229 | 177 | 47 | 9 | |||||
| Age, mean (SD) | 35 (13) | 33 (13) | 33 (14) | 34 (12) | 36 (11) | |||||
| Gender (male/female) | 33/28 | 1.2 | 80/149 | 0.5 | 67/110 | 0.6 | 23/24 | 1.0 | 4/5 | 0.8 |
| Diagnostics | ||||||||||
| Malaria postivea | na | 22 | 9.6 | 18 | 10.2 | 2 | 4.3 | 0 | 0.0 | |
| Filaria positivea | na | 20 | 8.7 | 18 | 10.2 | 0 | 0.0 | 0 | 0.0 | |
| Pulse, mean (SD) | 72 (11) | 76 (14) | 75 (13) | 75 (14) | 79 (16) | |||||
| Pulse>100 | 0 | 10 | 4.4 | 4 | 2.3 | 1 | 2.1 | 0 | 0.0 | |
| Blood pressure, mean systolic (SD) | 111 (13) | 107 (13) | 108 (15) | 105 (14) | 109 (24) | |||||
| Malaria pre-treatment b | ||||||||||
| Pyrimethamine/Sulfadoxine | na | 203 | 88.6 | 154 | 87.0 | 29 | 61.7 | 0 | 0.0 | |
| Amodiaquine | na | 4 | 1.7 | 6 | 3.4 | 0 | 0.0 | 0 | 0.0 | |
| Chloroquin | na | 2 | 0.9 | 2 | 1.1 | 0 | 0.0 | 0 | 0.0 | |
| Quinine | na | 9 | 3.9 | 7 | 4.0 | 18 | 38.3 | 9 | 100.0 | |
na: not applicable, tests not done or data not available
a
malaria and filaria testing are not standard and were only systematically applied in the DB289 trial series
b
other anti-parasitic treatment was administered during the 3 days prior to initiation of HAT treatment